Clinical characteristics and outcomes of lung transplantation in patients with severe COVID-19 infection: A systematic review and meta-analysis

IF 4.8 2区医学 Q1 INFECTIOUS DISEASES

International Journal of Infectious Diseases Pub Date : 2024-07-25 DOI:10.1016/j.ijid.2024.107176

{"title":"Clinical characteristics and outcomes of lung transplantation in patients with severe COVID-19 infection: A systematic review and meta-analysis","authors":"","doi":"10.1016/j.ijid.2024.107176","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>To synthesize the clinical experience of patients with COVID-19-associated acute respiratory distress syndrome (ARDS) or pulmonary fibrosis (PF) receiving lung transplantation (LTx) and compare the characteristics and outcomes of COVID-19 and non-COVID-19 LTx patients.</p></div><div><h3>Methods</h3><p>A literature search of online databases (PubMed, Web of Science, Embase, the Cochrane Library, China Science and Technology Journal Database, and Wan Fang databases) was performed regarding LTx for COVID-19–associated ARDS or PF. This study was registered on PROSPERO (CRD2024507647).</p></div><div><h3>Results</h3><p>Eight eligible studies were included with 478 COVID-19 LTx patients and 163 non-COVID-19 LTx patients. In COVID-19 LTx patients, the pooled hospital mortality and follow-up survival rate was 0.00% (95% CI 0.00-0.03) and 87.40% (95% CI 0.76-0.96). Compared to non-COVID-19 LTx patients, COVID-19 LTx patients were associated with significantly higher rate of primary graft dysfunction (odds ratio [OR] 8.72, 95% CI 3.54-21.47, <em>P <</em> 0.001) but significantly higher follow-up survival rate (OR 2.48, 95% CI 1.02-6.01, <em>P</em> = 0.04), within an overall similar follow-up period.</p></div><div><h3>Conclusions</h3><p>For patients with COVID-19–associated ARDS or PF, LTx offers acceptable short-term outcomes and is suggested as a viable lifesaving treatment.</p></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":4.8000,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1201971224002479/pdfft?md5=ec5f8f51be1c57dab0ab1ea6fbf2e240&pid=1-s2.0-S1201971224002479-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1201971224002479","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

To synthesize the clinical experience of patients with COVID-19-associated acute respiratory distress syndrome (ARDS) or pulmonary fibrosis (PF) receiving lung transplantation (LTx) and compare the characteristics and outcomes of COVID-19 and non-COVID-19 LTx patients.

Methods

A literature search of online databases (PubMed, Web of Science, Embase, the Cochrane Library, China Science and Technology Journal Database, and Wan Fang databases) was performed regarding LTx for COVID-19–associated ARDS or PF. This study was registered on PROSPERO (CRD2024507647).

Results

Eight eligible studies were included with 478 COVID-19 LTx patients and 163 non-COVID-19 LTx patients. In COVID-19 LTx patients, the pooled hospital mortality and follow-up survival rate was 0.00% (95% CI 0.00-0.03) and 87.40% (95% CI 0.76-0.96). Compared to non-COVID-19 LTx patients, COVID-19 LTx patients were associated with significantly higher rate of primary graft dysfunction (odds ratio [OR] 8.72, 95% CI 3.54-21.47, P < 0.001) but significantly higher follow-up survival rate (OR 2.48, 95% CI 1.02-6.01, P = 0.04), within an overall similar follow-up period.

Conclusions

For patients with COVID-19–associated ARDS or PF, LTx offers acceptable short-term outcomes and is suggested as a viable lifesaving treatment.

查看原文本刊更多论文

严重 COVID-19 感染患者的临床特征和肺移植结果：系统回顾和荟萃分析。

目的总结COVID-19相关急性呼吸窘迫综合征（ARDS）或肺纤维化（PF）患者接受肺移植（LTx）的临床经验，并比较COVID-19和非COVID-19 LTx患者的特征和预后：对在线数据库（PubMed、Web of Science、Embase、Cochrane Library、中国科技期刊数据库和万方数据库）中有关COVID-19相关ARDS或PF的LTx进行文献检索。该研究已在 PROSPERO（CRD2024507647）上注册：结果：共纳入了 8 项符合条件的研究，包括 478 名 COVID-19 LTx 患者和 163 名非 COVID-19 LTx 患者。在COVID-19 LTx患者中，汇总的住院死亡率和随访存活率分别为0.00%（95%CI 0.00-0.03）和87.40%（95%CI 0.76-0.96）。与非COVID-19 LTx患者相比，COVID-19 LTx患者的初次移植物功能障碍率明显更高（几率比[OR] 8.72，95%CI 3.54-21.47，P <0.001），但在总体相似的随访期内，随访生存率明显更高（OR 2.48，95%CI 1.02-6.01，P = 0.04）：结论：对于 COVID-19 相关 ARDS 或 PF 患者，LTx 可提供可接受的短期疗效，建议将其作为一种可行的挽救生命的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Infectious Diseases 医学-传染病学

CiteScore

18.90

自引率

2.40%

发文量

1020

审稿时长

30 days

期刊介绍： International Journal of Infectious Diseases (IJID) Publisher: International Society for Infectious Diseases Publication Frequency: Monthly Type: Peer-reviewed, Open Access Scope: Publishes original clinical and laboratory-based research. Reports clinical trials, reviews, and some case reports. Focuses on epidemiology, clinical diagnosis, treatment, and control of infectious diseases. Emphasizes diseases common in under-resourced countries.